silicosis treatment and prognosis

Silicosis Prognosis and Treatment

Silicosis prognosis and treatment often depend on how far the condition has progressed, as well as whether the condition has led to the development of any additional health concerns. Silicosis is a form of pneumoconiosis, meaning that it is a respiratory disease caused by inhaling particles of mineral dust (in this case, crystalline silica dust) that then settle into the lungs and cause inflammation and irreversible scarring. Over time, the scarring causes the lungs to become progressively more rigid, thereby making it more difficult to inhale and exhale.

The primary symptoms of silicosis include the following:

  • Increased production of mucus
  • Chronic cough
  • Shortness of breath
  • Chest pain

Additionally, someone living with silicosis is at increased risk of developing separate medical issues, including but not limited to respiratory failure, tuberculosis and lung cancer.

At the Lung Institute, we offer cellular therapy that not only can address the symptoms of silicosis, but also potentially slow the progression of the disease. We offer two types of minimally invasive cellular therapy — venous therapy and bone marrow therapy. Both therapies use autologous cells, meaning that the cells come directly from the patient’s own body. During venous therapy, we extract the cells from the patient’s blood. During bone marrow therapy, we extract them from the patient’s bone marrow. After extraction, we transfer the sample to our in-house lab, where we separate the cells from the patient’s remaining cells. Finally, we intravenously reintroduce the concentrated cells into the patient’s bloodstream. This entire process is performed on an outpatient basis over the course of two days.

If you would like to learn more about how the Lung Institute’s innovative cellular therapy for silicosis could potentially improve your symptoms and prognosis, please call us today at (800) 729-3065. We look forward to helping you breathe easier.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.